Kornimate/medical-research-clean huggingface dataset:
prospective, multicentre, open-label study evaluating 1.5 mg/day of fondaparinux.

Conditions: Major Orthopaedic Surgery and Renal Impairment

Summary: fondaparinux is an antithrombotic agent having already received a regulatory approval by the european authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (thr), total knee replacement (tkr), hip fracture (hf). the bleeding risk associated with this prescription is highly related to renal function evaluated by creatinin clearance (crcl). in order to reduce the bleeding risk, it has been proposed to prescribe fondaparinux 1.5 mg/day in patients with a crcl between 20 and 50ml/mn instead of 2.5mg/day (european mma). in the meantime, this approval is essentially based on simulated pharmakinetic data without any support of clinical data. prospective, multicentre, open-label study evaluating the safety profile of fondaparinux 1.5 mg/day, subcutaneously administered, in patients with a renal impairment defined by a crcl between 20 and 30 ml/min and undergoing a major orthopaedic surgery.

fondaparinux 1.5mg/day subcutaneously administered during post-surgery 1 to 10 days with the 1st treatment administration performed 6 to 8 hours after the end of surgery. screening visit : \> 7 days before inclusion visit if thr and tkr inclusion visit : day of surgery visits with blood drawing: 3 visits scheduled during 1 to 10 days of treatment period study end of treatment visit: d1 to d10 study end visit: 1 month ± 15 days

Eligibility criteria:
inclusion criteria: * • age \> 18 years old, * undergoing a major orthopaedic surgery (thr, tkr, hf) whatever procedure techniques are used, 1st indication or 2nd indication, * requiring an antithrombotic prophylaxis, * presenting a renal impairment defined by a creatinin clearance (crcl) between 20 and 50 ml/min calculated by cockcroft and gault's formula, * having signed the inform consent form. exclusion criteria: * contra-indications to fondaparinux, * history of heparin inducted thrombopenia (hit), * platelets \< 100 g/l.

Keywords: major orthopaedic surgery venous thromboembolic events prevention renal impairment arixtra anti-xa activity
evaluation of the prognostic impact of decreased serum beta2 microglobulin in the first year of follow-up of myeloproliferative neoplasia (prodige)

Conditions: Myeloproliferative Neoplasm

Summary: 50 patients with a diagnosis of mpn will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.


Eligibility criteria:
inclusion criteria: * mpn patient diagnosed at one of the participating centers * over 18 yo exclusion criteria: * not able to consent
regional activation of leukocytes in coronary artery disease

Conditions: Inflammation; Coronary Artery Disease

Summary: this study aims to evaluate the role of leukocyte activation in coronary artery disease

1. the primary aim of real cad is to determine regional differences of leukocyte activation in different vascular beds in vivo. 2. the secondary aim is to investigate differences in leukocyte activation between diabetic and cad subjects and patients suffering from both. 3. the third aim is to investigate the relationship between complement components, triglycerides and leukocyte activation markers in order to gain more insight into the causative processes leading to activation of leukocytes. 4. the fourth aim is to get more insight in the mbl genotypes and serum levels of cad and/or diabetic patients and the 'healthy' groups included in our study.

Eligibility criteria:
inclusion criteria: * subjects scheduled to undergo a coronary catheterization * provide written informed consent * aged \>18 and \<75 years * bmi \< 35 kg/m2 exclusion criteria: * emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. subjects who are not able to understand the patient information * crp \> 20 mg/l * unstable angina pectoris * cabg or ptca during the last 6 months * alcohol use \> 2 units/day * aberrations in kidney, liver and thyroid function * use of any experimental medication within 6 months of the catheterization * the use of immunosuppressive drugs
effects of exercise on cognitive function in glioma patients

Conditions: Low Grade Glioma of Brain; Anaplastic Glioma of Brain

Summary: the objective of this pilot randomized controlled trial (rct) is to assess the feasibility and to determine the effect size of an exercise program in improving objective cognitive functioning.

clinical stable patients with 1) low grade glioma (lgg) or 2) anaplastic glioma under age 70 will undergo a home-based exercise program (intervention) or will be assigned to the active controle group. patients in the intervention group will undergo a 6-month home-based exercise intervention. an individual exercise prescription will be based on the patients' level of aerobic fitness (vo2peak) as measured with cardiopulmonary testing (cpet; on a cycle ergometer with ecg and gas exchange measurement) at baseline. patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. session duration will vary between 20 minutes and 45 minutes. patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl. all primary and secondary outcomes will be assessed at baseline (t0; prior to randomization), and at completion of the 6-month exercise intervention (t1), and at a similar time-point for patients in the active control group. these will include indicators of feasibility (accrual, adherence, compliance and attrition), subjective and objective physical fitness measures, neuropsychological performance scores, and self-reported cognitive symptoms and mental wellbeing.

Eligibility criteria:
inclusion criteria: * grade ii and iii gliomas * age \< 50 years * karnofsky score \> or equal 80 * clinically stable for a minimum of 6 months prior to study entry * no recent anti-tumor treatment * interested in undergoing a physical exercise program * mild to moderate neuropsychological impairment based on normative comparison of objective test performance * relative vo2peak that leaves room for further improvement of cardiorespiratory fitness. exclusion criteria: * patients with serious orthopedic conditions or motor deficits * patients with serious cardiovascular, cardiopulmonary and neurological conditions (or risks) * patients judged to have psychiatric (including alcohol and drug abuse) * patients with severe cognitive problems * patients who report to engage in vigorous exercise (≥7 mets) for more than 20 minutes on at least 3 days per week on a regular basis will be excluded for assessment purposes, study participants will need to have basic fluency in the dutch language.
optimal coronary flow after pci for myocardial infarction - a pilot study

Conditions: ST-segment Elevation Myocardial Infarction

Summary: in this study the investigators test the hypothesis that alteplase given intra coronary after pci reduce infarct size in patients with st-elevation myocardial infarction(stemi) and impaired microvascular function defined as a value of index of microvascular resistance (imr) \>30.

after coronary stenting, index of microvascular resistance (imr) will be measured invasively. patients with imr \>30 will be randomised to 20 mg alteplase or placebo (nacl) administered in the culprit vessel through a microcatheter. magnet resonance imaging (mri) of the myocardium will be performed early (2-6 days) and late (3 months) to estimate the primary endpoint (infarct size). 10 non-randomised patients, with imr \<30, will undergo the same follow-up as the randomised patients. clinical events for all randomised and non-randomised patients will be collected from swedish national registries and by telephone at 3 and 12 months.

Eligibility criteria:
criteria for randomization: 1. imr measured in culprit vessel \> 30 criteria for imr measurement: inclusion criteria: 1. oral and signed informed consent 2. males and females 18 - 85 years of age 3. diagnosis of st-elevation myocardial infarction (stemi) including occlusion of culprit vessel on angiography 4. onset of continuous symptoms within 12 hours 5. have undergone pci of culprit vessel 6. subjects are willing to comply with scheduled visits and tests and are able and willing to provide informed consent exclusion criteria: 1. previously known ejection fraction \<30% 2. previous pci in the culprit vessel 3. chronic total occlusion in major vessel 4. any history of bleeding diathesis, known coagulopathy, or will refuse blood transfusions 5. recent history or known platelet count \<100.000 cells/mm3 or hbg \< 10 g/dl 6. known reduced kidney function with estimated glomerular filtration rate (gfr) \<30 ml/min/1.73m2. 7. previous hemorrhagic stroke 8. ongoing oral anticoagulation treatment 9. severe asthma requiring daily treatment 10. any mechanical complication (e.g. ventricular septal defect, papillary muscle rupture, cardiac tamponade) 11. atrioventricular block grade iii 12. known inability to undergo mri investigation permanent pacemaker * pronounced claustrophobia 13. known intolerance to study drug 14. known intolerance to adenosine 15. pregnancy 16. participation in another investigational drug study 17. previous randomization in the optimal-pci trial
comparison between continuous infusion and intermittent bolus injection of propofol for deep sedation during ercp

Conditions: Biliary Tract Diseases; Pancreatic Diseases

Summary: the aim of this study is to compare sedation efficiency, safety and satisfaction by both endoscopist, assistants, and the patients between continuous infusion and intermittent bolus injection of propofol for deep sedation during ercp.

the patients undergone ercp were randomly assigned to either continuous infusion of propofol (continuous group) or midazolam plus intermittent bolus injection of propofol (intermittent group) for deep sedation. in the continuous group, propofol was continuously administered via infusion pump and the doses were determined by sedation assistants monitoring the patients. in the intermittent group, a loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol was initially injected and repeated bolus injection of 20 mg of propofol was followed according to patients' sedation level. sedation related parameters (total dose of propofol, induction/recovery time, patients' cooperation) and adverse events during the procedure were evaluated. satisfaction scores by endoscopist, assistant, and patients and difficulty scores of maintaining the sedation by assistants were also graded after the procedure.

Eligibility criteria:
inclusion criteria: * patients undergone ercp for biliary and pancreatic diseases exclusion criteria: * comorbid conditions of asa class 4-5 * age under 18 years or over 90 years * pregnancy * past medication history of benzodiazepine or narcotics * known allergy to midazolam or propofol * hypotension (systolic blood pressure \<90 mmhg), hypoxemia (sao2 \<90%), or bradycardia (50/min) at baseline measurements

Keywords: cholangiopancreatography endoscopic retrograde
eus-guided ethanol-lipiodol ablation of pancreatic neuroendocrine tumor: a prospective study

Conditions: Efficacy; Safety; Feasibility

Summary: the present study evaluate the safety and efficacy of eus-guided ethanol-lipiodol ablation for the treatment of pancreatic net

pancreatic neuroendocrine tumor, including insulinoma, increasingly are being encountered in clinical practice. management of pancreatic net is challenging because most are asymptomatic but may have malignant potential, and surgical resection of pancreatic neoplasm is associated with substantial morbidity of 20%-40% and a mortality rate of 2%. management strategy needs to be individualized, applying a risk-benefit analysis to each patient. recently, pancreatic tissue ablation by eus-guided injection of ethanol or other chemotherapeutic agents can be performed safely, with few procedure-related complications. levy et al. demonstrated that eus-guided ethanol ablation for insulinoma was both safe and feasible, and symptomatic improvement was achieved in 8 of 8 patients (100%). however, previous study have included only a small number of patients and evaluated only short-term outcomes. in addition, lipiodol permits the drug to concentrate in the tumor. to obtain an embolic effect and prevent washout of the ethanol, ethanol/lipiodol mixture is administered into the tumor. the present study evaluate the safety and efficacy of eus-guided ethanol-lipiodol ablation for the treatment of pancreatic net

Eligibility criteria:
inclusion criteria: * pancreas net(including insulinoma) \< 2cm in diameter * poor surgical candidate (involving the head of the pancreas or multifocal net, advanced comorbidity, age \>75 years of age) * refuse to surgery exclusion criteria: * younger than 18 years of age * coagulopathy (inr \>1.5, platelet \<50,000) * evidence of active pancreatitis * inability to safely undergo eus * refuse to participate

Keywords: neuroendocrine tumor ethanol endoscopic ultrasonography
sti knowledge and hpv vaccine acceptance in bamako, mali in 2012

Conditions: HPV; HPV-Related Cervical Carcinoma

Summary: although screening for pre-cancerous cervical lesions and human papilloma virus (hpv) vaccination are accepted and effective means to prevent cervical cancer, women in mali have limited access to these interventions. in addition, cervical cancer prevention by hpv vaccination has been controversial in some settings. to reduce cervical cancer prevalence and increase hpv vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. in this study, the level of knowledge about hpv and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in bamako, mali. the survey was combined with a brief educational session on hpv. prior to the education session, overall knowledge of hpv infection and cervical cancer was very low: only 8% knew that hpv is a sexually transmitted infection (sti). less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. after hearing a description of hpv vaccine, more than 80% would accept hpv vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. this study provides information on sti knowledge and vaccine acceptance in bamako, mali in 2012, prior to the introduction of hpv vaccination.


Eligibility criteria:
inclusion criteria: * 12-17 years of age, with guardian consent * 18 years or older * male or female * living in mèkin-sikoro and djikoroni exclusion criteria: * 12-17 years of age, without guardian consent * \<12 years of age * living outside mèkin-sikoro and djikoroni

Keywords: mali bamako survey
exercise training in children with corrective cardiac surgeries

Conditions: Quality of Life; Congenital Heart Disease; Heart; Surgery, Heart, Functional Disturbance as Result

Summary: to determine the effects of preoperative exercise therapy on postoperative cardiopulmonary outcomes and quality of life in children with corrective cardiac surgeries.within literature there is limited evidence on preoperative exercise therapy in the pediatric population, positive results of the study can introduce a new tradition of preoperative exercise therapy and significantly reduce post-operative complications. secondary complications would also be addressed in the study, a positive result can reduce the total costs by reducing hospital stays and improving the quality of life of child.

cardiac surgeries are often associated with some post-operative cardiopulmonary complications most often cardiac arrhythmias, pulmonary atelectasis, and hospital induced pneumonia and reduced inspiratory capacities which can be reduced by exercise therapy this study is therefore significant not only for the determination of the effects of preoperative exercise therapy, it will also provide a path toward pre-habilitation followed by effective postoperative cardiac rehabilitation which is mostly lacking in many setups.

Eligibility criteria:
inclusion criteria: * diagnosed with congenital heart disease * undergoing elective corrective cardiac surgery * vitally stable exclusion criteria: * having acquired heart disease or undergoing emergency cardiac surgeries * patients undergoing valvular repairing surgeries * functional status is limited due to conditions other than chd or having any contraindications * inability to adhere to study protocols * participants who refused or withdrew from the study

Keywords: cardiopulmonary outcomes corrective cardiac surgeries preoperative exercise therapy
outcomes of mastoid obliteration canal wall down tympanomastoidectomy in cholesteatoma surgery

Conditions: Cholesteatoma

Summary: randomised study to evaluate the outcomes of mastoid cavity obliteration by muscle versus bone in canal wall down tympanomastoidectomy in cholesteatoma surgery

regarding discharge time of epithelizqtion hearing outcomes quality of life

Eligibility criteria:
inclusion criteria: * all patients who have extensive or recuutrent cholesteatoma undergoing canal wall down tympanomastoidectomy exclusion criteria: * not willing for surgery * malignancy * patients with intracranial complication * residual cholesteatoma
cytological diagnosis of hepatic angiosarcoma and its histopathologic correlation

Conditions: Hepatic Angiosarcoma

Summary: cytological diagnosis of hepatic angiosarcoma by fine-needle aspiration (fna) or imprint cytology is difficult due not only to its various cytomorphologic features but also clinical rarity. vasoformative features, such as pseudo-acini, branching pseudo-capillary structure, and intracytoplasmic lumina, are clues to achieve the diagnosis. but these features are not always present. in order to find clues for cytological diagnosis of angiosarcoma, we collected cases of hepatic angiosarcoma to study their cytological features. and then compared these features with those in their histopathological biopsy or resection.

hepatic angiosarcoma is a rare hepatic malignant tumor. although diagnosis of hepatic angiosarcoma by fna cytology has been reported since 1982, followed by several studies, its cytomorphologic features were still not well recognized by cytopathologists because of its clinical rarity and various morphologic features. we reviewed literatures about cytomorphology of hepatic angiosarcoma by fna. there are only 11 cases retrieved in 10 articles searched from medline. the sex m/f ratio was 6/4 (one unknown); age range was 56 to 79 years old. in initial cytological evaluation, four cases got angiosarcoma or consistent/suspicious angiosarcoma diagnosis. positive for malignancy, sarcoma, and poorly differentiated spindle cell lesion were in one case respectively. one was diagnosed as atypical cells. remaining three were unavailable by their reports. in cytological morphologic features, all but one met least 2 of 3 cytological cellular criteria of angiosarcoma cells: spindle cells, epithelioid cells, and pleomorphic cells. in cytological architectural features, 7 of 11 cases showed vasoformative structures; 5 of 11 cases showed intracytoplasmic lumen or erythrophagocytosis. ten of 11 cases had histologic/pathologic confirmation as angiosarcoma. one case reported interrelation of tumor structures and their own accompanied liver tissue in cell blocks.

Eligibility criteria:
inclusion criteria: consecutive patients of hepatic angiosarcoma performed fna and/or imprint cytological examinations in our hospital. exclusion criteria: 1. patients without pathological confirmation. 2. patients who are not angiosarcoma by pathological reviews.

Keywords: angiosarcoma cytology liver cancer
study of the sars-cov-2 (covid-19) serological profile of an army training hospital staff

Conditions: Sars-CoV2

Summary: emerging in china in december 2019, covid-19, whose pathogen is sars-cov-2, was declared a global pandemic in march 2020. the clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. transmission occurs through droplets, with a r0 of approximately 3. rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. health care institutions are places at risk of covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. in order to protect personnel, hygiene measures were immediately recalled and reinforced. this study is aimed at evaluating the incidence rate of anti-sars-cov2 seroconversion over 2 months among hospital staff, without any supposed anti-covid treatment 19.


Eligibility criteria:
inclusion criteria: * army training hospital staff exclusion criteria: * individuals who have already been confirmed covid-19 positive * individuals taking preventive anti-covid-19 therapy or considering participating in anti-covid-19 therapy study * individuals on hydroxychloroquine * pregnant or breastfeeding women * non-permanent staff during the study period * individuals identified for a detachment outside the metropole during the study period
dpp-4 inhibition, incretins and islet function

Conditions: Type 2 Diabetes

Summary: hypothesis is that dpp-4 inhibition affects glucose levels through changes in incretin and islet hormones. the study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different dpp-4 inhibitors and placebo.

the study is a single-center study with a cross-over design to examine glycemia, incretin hormones and islet hormones over a 24h study period with standardized breakfast, lunch and dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.

Eligibility criteria:
inclusion criteria: * • caucasian men or women with type 2 diabetes diagnosed according to icd10 at time of inclusion * ongoing treatment with life style adjustment including diet and exercise regimen together with metformin as oral antidiabetic . metformin therapy should be stable the last three months * age 40-75 years * hba1c 52-80 mmol/mol (inclusive) * bmi: 20-40 kg/m2 * written informed consent has been given * capability and willingness to participate in the whole study exclusion criteria: * • liver disease (k70-77 in icd10) or liver enzymes three times above upper reference range * diabetic nephropathy (gfr \< 30 ml/min/1.73 m2 or albuminuria) or other causes of renal disease * proliferative diabetic retinopathy * treatment with any glucose-lowering medication except metformin * previous myocardial infarction, coronary heart disease or instable angina pectoris in the last 6 months. * symptomatic heart failure (nyha class ii-iii) * previous surgery on the gastrointestinal tract * larger surgical intervention during the last 12 weeks * female subject who are pregnant or breast feeding * women of child bearing potential not using a highly effective method of birth control * treatment with oral steroids, thiazide diuretics, digoxin or growth hormone * hypersensitivity to the active substances of to any of the excipients * participation in another study the last 4 weeks * smoker * paracetamol intolerance